The Use of Albuterol/Budesonide as Reliever Therapy to Reduce Asthma Exacerbations
Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved..
Prevention of asthma exacerbations and reduction of systemic corticosteroid burden remain unmet needs in asthma. US asthma guidelines recommend concomitant short-acting β2-agonist (SABA) and inhaled corticosteroid (ICS) as an alternative reliever at step 2. The Food and Drug Administration approved a pressurized metered-dose inhaler containing albuterol and budesonide for as-needed treatment or prevention of bronchoconstriction and for reducing exacerbation risk in patients with asthma aged ≥18 years. This combination is approved for use as a reliever with or without maintenance therapy, but it is not indicated for maintenance therapy (or for single maintenance and reliever therapy). Intervening with as-needed SABA-ICS during the window of opportunity to reduce inflammation during loss of asthma control can reduce exacerbation risk, by exerting both genomic and nongenomic anti-inflammatory effects. We propose that the use of albuterol-budesonide rather than albuterol as a reliever to manage episodic symptoms driven by acute bronchoconstriction and airway inflammation can improve outcomes. This combination approach, shown to decrease asthma exacerbations and oral corticosteroid burden in patients with moderate-to-severe asthma, represents a paradigm shift for asthma treatment in the United States. Further safety and efficacy studies should provide evidence that this type of reliever should be standard of care.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
The journal of allergy and clinical immunology. In practice - 12(2024), 4 vom: 15. Apr., Seite 882-888 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Panettieri, Reynold A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaip.2024.01.043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368054411 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368054411 | ||
| 003 | DE-627 | ||
| 005 | 20240409232417.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240206s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaip.2024.01.043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM368054411 | ||
| 035 | |a (NLM)38316182 | ||
| 035 | |a (PII)S2213-2198(24)00145-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Panettieri, Reynold A |c Jr |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Use of Albuterol/Budesonide as Reliever Therapy to Reduce Asthma Exacerbations |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Prevention of asthma exacerbations and reduction of systemic corticosteroid burden remain unmet needs in asthma. US asthma guidelines recommend concomitant short-acting β2-agonist (SABA) and inhaled corticosteroid (ICS) as an alternative reliever at step 2. The Food and Drug Administration approved a pressurized metered-dose inhaler containing albuterol and budesonide for as-needed treatment or prevention of bronchoconstriction and for reducing exacerbation risk in patients with asthma aged ≥18 years. This combination is approved for use as a reliever with or without maintenance therapy, but it is not indicated for maintenance therapy (or for single maintenance and reliever therapy). Intervening with as-needed SABA-ICS during the window of opportunity to reduce inflammation during loss of asthma control can reduce exacerbation risk, by exerting both genomic and nongenomic anti-inflammatory effects. We propose that the use of albuterol-budesonide rather than albuterol as a reliever to manage episodic symptoms driven by acute bronchoconstriction and airway inflammation can improve outcomes. This combination approach, shown to decrease asthma exacerbations and oral corticosteroid burden in patients with moderate-to-severe asthma, represents a paradigm shift for asthma treatment in the United States. Further safety and efficacy studies should provide evidence that this type of reliever should be standard of care | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-inflammatory reliever | |
| 650 | 4 | |a As-needed | |
| 650 | 4 | |a Flares | |
| 650 | 4 | |a Inhaled corticosteroids | |
| 650 | 4 | |a Nongenomic | |
| 650 | 4 | |a Reliever | |
| 650 | 4 | |a Rescue | |
| 650 | 4 | |a Short-acting β(2)-agonist | |
| 650 | 7 | |a Budesonide |2 NLM | |
| 650 | 7 | |a 51333-22-3 |2 NLM | |
| 650 | 7 | |a Albuterol |2 NLM | |
| 650 | 7 | |a QF8SVZ843E |2 NLM | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Ethanolamines |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Formoterol Fumarate |2 NLM | |
| 650 | 7 | |a W34SHF8J2K |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 700 | 1 | |a Chipps, Bradley E |e verfasserin |4 aut | |
| 700 | 1 | |a Skolnik, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a George, Maureen |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Lugogo, Njira |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of allergy and clinical immunology. In practice |d 2013 |g 12(2024), 4 vom: 15. Apr., Seite 882-888 |w (DE-627)NLM227247523 |x 2213-2201 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:882-888 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaip.2024.01.043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2024 |e 4 |b 15 |c 04 |h 882-888 | ||